Can Tirzepatide Cause Diabetes — or Does It Work the Other Way?

Does tirzepatide raise blood sugar in people without diabetes?

No published evidence shows tirzepatide causing diabetes in people who did not already have it. The mechanism runs firmly the other way. Tirzepatide co-activates GIP and GLP-1 receptors, both of which are involved in prompting the pancreas to release insulin in response to meals and in suppressing the liver's release of glucose between meals. The result, seen consistently across the SURMOUNT programme, is lower fasting glucose and improved insulin sensitivity as weight falls.

In SURMOUNT-1, which followed adults with obesity but without diabetes for 72 weeks, fasting serum glucose and HbA1c fell across all active treatment groups, and a proportion of participants who had entered the trial with prediabetes showed glucose readings that normalised by the end. The NHS's patient information on tirzepatide reflects this profile, describing blood-sugar lowering as part of how the medicine works rather than as an incidental effect. If you are looking at the broader relationship between the drug and glucose metabolism, our overview of tirzepatide and diabetes covers the licensed indications in full detail.

The short answer for someone without diabetes: tirzepatide is not going to tip you into it. The clinical concern, if any, sits on the other side of the ledger.

What happens to blood sugar when tirzepatide is stopped?

This is the part of the question that often gets missed. When people lose a significant amount of weight on tirzepatide, their insulin sensitivity typically improves and their fasting glucose falls. If treatment stops (particularly after many months) weight can return, and with it, some of the metabolic changes that were improving. For someone who had prediabetes or early-stage type 2 diabetes before starting treatment, that rebound matters.

This is not a reason to avoid tirzepatide. It is a reason to treat the decision to stop as a clinical one. A prescriber reviewing your case before you come off treatment can arrange appropriate blood-glucose follow-up, adjust any other medicines you are taking, and discuss whether a planned tapering approach suits your situation better than stopping overnight. If you are already managing type 2 diabetes, our page on tirzepatide for type 2 diabetes explains how blood-sugar monitoring is built into treatment from the outset.

The MHRA's published patient guidance on tirzepatide, available through the NHS medicines pages, notes that doses of existing diabetes medicines may need adjusting when starting tirzepatide, and that the same logic applies in reverse when stopping it.

Is there a risk of hypoglycaemia rather than high blood sugar?

For most people taking tirzepatide for weight management alone, hypoglycaemia (low blood sugar) is not a significant risk from tirzepatide itself. The medicine stimulates insulin release in a glucose-dependent way, meaning it scales back that stimulus when blood-sugar levels are already low. That is a meaningful safety feature compared with older classes of diabetes medicine.

The risk picture changes if tirzepatide is taken alongside a sulphonylurea or insulin. Both of those medicines lower blood sugar independently of glucose levels, and when combined with tirzepatide's additional effect, the combined result can push glucose lower than intended. The NHS guidance on tirzepatide and the prescribing information both flag this clearly: doses of those co-prescribed medicines may need reducing when tirzepatide is started. Your prescriber handles that adjustment; it is not something to manage unilaterally at home.

People sometimes notice mild dizziness or light-headedness when starting tirzepatide, particularly on dose increases. This is most commonly related to the gastrointestinal effects of the medicine rather than blood-sugar fluctuation, but if you are uncertain, checking your blood sugar or speaking to a clinician rules out any confusion quickly. Our prescribers at our clinical team are available to review concerns like this, and our support line is open seven days a week.

Who should be especially careful about blood-sugar changes on tirzepatide?

Three groups warrant closer monitoring. First, people who already have type 2 diabetes and are on glucose-lowering medicines, the interaction question above applies directly, and their prescriber needs to coordinate medication adjustments from day one. Second, people with a diagnosis of prediabetes or a family history that makes them higher risk: tirzepatide is likely to help their metabolic picture, but that trajectory should be tracked. Third, anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide at all, this is a contraindication listed in the prescribing information, unrelated to blood sugar but important to state clearly on any safety page.

Tirzepatide is not licensed for people under 18, and it is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. For anyone in those groups, the medicine should not be started, and anyone who becomes pregnant while on treatment should speak to their GP or specialist promptly. For a fuller picture of how tirzepatide is used for diabetes, including where it sits within clinical guidelines and which patient groups it is licensed for, our dedicated overview explains the evidence in detail. And if a question sitting in your mind tonight is about whether you can drink alcohol on Mounjaro, that page covers how alcohol interacts with the medicine and what to be aware of, and if you have questions about how tirzepatide relates to type 1 diabetes, that page covers the specific considerations and evidence for that group, and if a question sitting in your mind tonight is about whether Mounjaro itself can cause diabetes, that page covers the same ground through the brand-name lens most people use when searching.

A clinical assessment with a GPhC-registered prescriber is the right way to resolve which of these considerations applies to you personally. You can speak to our prescribers through a free consultation, reviewed the same day your answers are submitted.